ArticleJournal of biomolecular screening2014
Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses.
Article in Journal of biomolecular screening, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Reassessing pharmacogenomic cell sensitivity with multilevel statistical models.Biostatistics (Oxford, England) · 2023Article
- Predicting compound activity from phenotypic profiles and chemical structures.Nature communications · 2023Article
- Systematic identification of biomarker-driven drug combinations to overcome resistance.Nature chemical biology · 2022Article
- Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity.ACS chemical biology · 2022Article
- The Use of Informer Sets in Screening: Perspectives on an Efficient Strategy to Identify New Probes.SLAS discovery : advancing life sciences R & D · 2021Article
- A database framework for rapid screening of structure-function relationships in PFAS chemistry.Scientific data · 2021Article
- QSAR-derived affinity fingerprints (part 1): fingerprint construction and modeling performance for similarity searching, bioactivity classification and scaffold hopping.Journal of cheminformatics · 2020Article
- Predicting kinase inhibitors using bioactivity matrix derived informer sets.PLoS computational biology · 2019Article
- Encircling the regions of the pharmacogenomic landscape that determine drug response.Genome medicine · 2019Article
- Small-molecule targeting of brachyury transcription factor addiction in chordoma.Nature medicine · 2019Article
- Computational Analyses Connect Small-Molecule Sensitivity to Cellular Features Using Large Panels of Cancer Cell Lines.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening.Briefings in bioinformatics · 2018Review
- Article
- Article
- bioassayR: Cross-Target Analysis of Small Molecule Bioactivity.Journal of chemical information and modeling · 2016Article
- Correlating chemical sensitivity and basal gene expression reveals mechanism of action.Nature chemical biology · 2016Article
- The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods.Cell chemical biology · 2016Review
- Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.Cancer discovery · 2015Article
- Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery.Trends in genetics : TIG · 2015Review
- NAMPT is the cellular target of STF-31-like small-molecule probes.ACS chemical biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
High-throughput screening allows rapid identification of new candidate compounds for biological probe or drug development. Here, we describe a principled method to generate "assay performance profiles" for individual compounds that can serve as a basis for similarity searches and cluster analyses. Our method overcomes three challenges associated with generating robust assay performance profiles: (1) we transform data, allowing us to build profiles from assays having diverse dynamic ranges and variability; (2) we apply appropriate mathematical principles to handle missing data; and (3) we mitigate the fact that loss-of-signal assay measurements may not distinguish between multiple mechanisms that can lead to certain phenotypes (e.g., cell death). Our method connected compounds with similar mechanisms of action, enabling prediction of new targets and mechanisms both for known bioactives and for compounds emerging from new screens. Furthermore, we used Bayesian modeling of promiscuous compounds to distinguish between broadly bioactive and narrowly bioactive compound communities. Several examples illustrate the utility of our method to support mechanism-of-action studies in probe development and target identification projects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.